MarginsXMarginsX
Home › Markets › Health Care › RGEN

Repligen Corporation (RGEN)

RGEN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$162.78
-2.99% on the day
Market cap
$10.4B
Large cap
Revenue · 2025
$738.3M
+16.4% on 2024
Net income · 2025
$48.9M
6.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/0001193125-26-076528-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRGEN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year1986
SEC CIK0000730272
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$738.3M
Net income$48.9M
Operating income$55.2M
Net margin6.6%
Operating margin7.5%
Revenue growth+16.4%
Cash$566.0M
Total assets$2.9B
P/E (computed)212.8×
P/S (computed)14.1×

Warning signs

Cash runway
Cash-flow positive
$727.0M cash at September 30, 2026
Share count, 1 year
+13.6%
2025-10-31 to 2026-10-23 · +14.5% over 3 years
Going-concern doubt
No
10-Q filed October 30, 2026
Insider net buying, 12 months
-$14.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-30
Cash and burn$727.0M cash; operating cash flow $32.5M a quarter.Report 2026-09-30
Shares outstanding63,923,738 (2026-10-23); 56,290,749 a year earlier; 55,832,013 three years earlier.Cover page 2026-10-23
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-11
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $14.2M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$209.3M-$38.4M$43.1M$727.0M$555.6M$805.6M10-Q 2026-10-30
Q2 2026
2026-06-30
$204.1M$5.0M$32.8M$606.8M$551.0M$785.1M10-Q 2026-07-29
Q1 2026
2026-03-31
$194.3M$8.3M$28.3M$582.6M$546.6M$763.3M10-Q 2026-05-06
Q4 2025
2025-12-31
$197.9M$13.3M$25.7M$566.0M$542.2M$738.3M10-K 2026-02-26
Q3 2025
2025-09-30
$188.8M$14.9M$48.1M$748.7M$537.9M$707.9M10-Q 2026-10-30
Q2 2025
2025-06-30
$182.4M$14.9M$28.6M$708.9M$533.7M$674.0M10-Q 2026-07-29
Q1 2025
2025-03-31
$169.2M$5.8M$15.0M$697.2M$529.6M$650.4M10-Q 2026-05-06
Q4 2024
2024-12-31
$167.5M-$33.9M$39.2M$757.4M$525.6M$634.4M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-09-04
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-10-30
Latest current report8-K2026-11-06
Latest proxyDEFA14A2026-04-27

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.3%
1 month-4.3%
3 months+0.2%
Year to date+2.4%
1 year+11.4%
From 52-week high-13.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
QGENQiagen N.V. Common Shares$49.81-0.16%$10.3B
KYMRKymera Therapeutics Inc.$125.85-1.35%$10.7B
HALOHalozyme Therapeutics Inc.$96.50-3.76%$11.0B
PCVXVaxcyte Inc.$61.61-2.78%$9.8B
TECHBio-Techne Corp$72.79-0.01%$11.4B
KRYSKrystal Biotech Inc.$297.90-2.40%$8.8B
CGONCG Oncology Inc.$84.78+13.95%$7.6B
TWSTTwist Bioscience Corporation$105.04-5.88%$7.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier